Tumor classification: molecular analysis meets Aristotle - PubMed (original) (raw)
Tumor classification: molecular analysis meets Aristotle
Jules J Berman. BMC Cancer. 2004.
Abstract
Background: Traditionally, tumors have been classified by their morphologic appearances. Unfortunately, tumors with similar histologic features often follow different clinical courses or respond differently to chemotherapy. Limitations in the clinical utility of morphology-based tumor classifications have prompted a search for a new tumor classification based on molecular analysis. Gene expression array data and proteomic data from tumor samples will provide complex data that is unobtainable from morphologic examination alone. The growing question facing cancer researchers is, "How can we successfully integrate the molecular, morphologic and clinical characteristics of human cancer to produce a helpful tumor classification?"
Discussion: Current efforts to classify cancers based on molecular features ignore lessons learned from millennia of experience in biological classification. A tumor classification must include every type of tumor and must provide a unique place for each tumor within the classification. Groups within a classification inherit the properties of their ancestors and impart properties to their descendants. A classification was prepared grouping tumors according to their histogenetic development. The classification is simple (reducing the complexity of information received from the molecular analysis of tumors), comprehensive (providing a place for every tumor of man), and consistent with recent attempts to characterize tumors by cytogenetic and molecular features. The clinical and research value of this historical approach to tumor classification is discussed.
Summary: This manuscript reviews tumor classification and provides a new and comprehensive classification for neoplasia that preserves traditional nomenclature while incorporating information derived from the molecular analysis of tumors. The classification is provided as an open access XML document that can be used by cancer researchers to relate tumor classes with heterogeneous experimental and clinical tumor databases.
Similar articles
- Mixture classification model based on clinical markers for breast cancer prognosis.
Zeng T, Liu J. Zeng T, et al. Artif Intell Med. 2010 Feb-Mar;48(2-3):129-37. doi: 10.1016/j.artmed.2009.07.008. Epub 2009 Dec 14. Artif Intell Med. 2010. PMID: 20005686 - Tumor classification using phylogenetic methods on expression data.
Desper R, Khan J, Schäffer AA. Desper R, et al. J Theor Biol. 2004 Jun 21;228(4):477-96. doi: 10.1016/j.jtbi.2004.02.021. J Theor Biol. 2004. PMID: 15178197 - Tumor taxonomy for the developmental lineage classification of neoplasms.
Berman JJ. Berman JJ. BMC Cancer. 2004 Nov 30;4:88. doi: 10.1186/1471-2407-4-88. BMC Cancer. 2004. PMID: 15571625 Free PMC article. - The 2007 WHO classification of tumors of the central nervous system - what has changed?
Rousseau A, Mokhtari K, Duyckaerts C. Rousseau A, et al. Curr Opin Neurol. 2008 Dec;21(6):720-7. doi: 10.1097/WCO.0b013e328312c3a7. Curr Opin Neurol. 2008. PMID: 18989119 Review. - Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?
Biganzoli L, Claudino WM, Pestrin M, Pozzessere D, Di Leo A. Biganzoli L, et al. Crit Rev Oncol Hematol. 2007 Apr;62(1):1-8. doi: 10.1016/j.critrevonc.2006.10.004. Epub 2007 Feb 21. Crit Rev Oncol Hematol. 2007. PMID: 17317203 Review.
Cited by
- Dissociation protocols used for sarcoma tissues bias the transcriptome observed in single-cell and single-nucleus RNA sequencing.
Truong DD, Lamhamedi-Cherradi SE, Porter RW, Krishnan S, Swaminathan J, Gibson A, Lazar AJ, Livingston JA, Gopalakrishnan V, Gordon N, Daw NC, Navin NE, Gorlick R, Ludwig JA. Truong DD, et al. BMC Cancer. 2023 May 31;23(1):488. doi: 10.1186/s12885-023-10977-1. BMC Cancer. 2023. PMID: 37254069 Free PMC article. - Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial.
Bielcikova Z, Stursa J, Krizova L, Dong L, Spacek J, Hlousek S, Vocka M, Rohlenova K, Bartosova O, Cerny V, Padrta T, Pesta M, Michalek P, Hubackova SS, Kolostova K, Pospisilova E, Bobek V, Klezl P, Zobalova R, Endaya B, Rohlena J, Petruzelka L, Werner L, Neuzil J. Bielcikova Z, et al. EClinicalMedicine. 2023 Feb 23;57:101873. doi: 10.1016/j.eclinm.2023.101873. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 37064512 Free PMC article. - Association between cancer genes and germ layer specificity.
Lee H, Lee S, Cho WJ, Shin M, Park L. Lee H, et al. Med Oncol. 2022 Sep 29;39(12):218. doi: 10.1007/s12032-022-01823-8. Med Oncol. 2022. PMID: 36175592 - ZC3HC1 Is a Novel Inherent Component of the Nuclear Basket, Resident in a State of Reciprocal Dependence with TPR.
Gunkel P, Iino H, Krull S, Cordes VC. Gunkel P, et al. Cells. 2021 Jul 30;10(8):1937. doi: 10.3390/cells10081937. Cells. 2021. PMID: 34440706 Free PMC article. - Nimbolide inhibits tumor growth by restoring hepatic tight junction protein expression and reduced inflammation in an experimental hepatocarcinogenesis.
Ram AK, Vairappan B, Srinivas BH. Ram AK, et al. World J Gastroenterol. 2020 Dec 7;26(45):7131-7152. doi: 10.3748/wjg.v26.i45.7131. World J Gastroenterol. 2020. PMID: 33362373 Free PMC article.
References
- Director's challenge: toward a molecular classification of tumors http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-98-027.html
- Mayr E. The growth of biological thought: diversity, evolution and inheritance. Cambridge: Belknap Press; 1982.
- Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947. doi: 10.1056/NEJMoa012914. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources